Alternating PET-CT and CT — A Practical Plan for Long-Term Surveillance

Yes, and it is a reasonable question. Ask your oncologist which follow-up visits need PET-CT and which could use CT instead. Many surveillance protocols already alternate the two. If yours does not, your oncologist should be able to explain why — and if there is no strong clinical reason, a schedule change may be possible. Bringing the question up specifically, rather than as a general cost concern, makes the conversation more productive.

Not when the alternation is planned rather than decided by you alone. CT reliably detects new masses and growth in stable anatomy. PET-CT adds most where anatomy is ambiguous — such as after surgery or radiotherapy — or when metabolic activity is the specific question. A missed recurrence is far more likely from skipping scans altogether than from using CT at intervals where CT is the appropriate test.

PET-CT adds most in cancers where distinguishing scar tissue from active disease matters, and where metabolic response predicts outcome. Lymphoma is one clear example — ESMO guidelines use PET-CT for restaging but often move to CT for later intervals once remission is confirmed. For lung cancer, head and neck cancer and certain other types, the guidance varies by stage and protocol. Ask your oncologist whether your cancer type is one where PET-CT at every visit is supported by current evidence.

Structurally, yes — at every centre — because CT does not require a radiotracer. PET imaging uses a radioactive tracer, typically FDG, that must be manufactured at a specialist facility and used within hours. That production cost is present in every PET-CT regardless of where you have it done. Indicative costs vary by city and centre, and any figure quoted today should be treated as a guide rather than a guarantee.

PET-CT adds most when CT findings are ambiguous — when a mass is present but it is unclear whether it is scar tissue or active cancer. It is also preferred when the cancer is known to spread to sites that CT detects poorly, when the question is whether treatment has worked, and when a clinical decision such as whether to operate depends on knowing whether a lesion is metabolically active. Cost should not be the reason to avoid it when the clinical question requires it.

We cannot give a single number because dose varies with the scanner, the body area covered and the protocol used. What is consistent across ICRP and ASCO guidance is that PET-CT involves a higher dose than CT alone, because it adds a radiotracer to the CT component. For most patients having occasional scans, the individual risk is small. For patients with years of surveillance ahead, reducing unnecessary PET-CT appointments — where CT answers the question equally well — is a reasonable goal your oncologist can build into your plan.